Two PARP Inhibitors OK’d for New Prostate Cancer Indication

Although poly ADP-ribose polymerase (PARP) inhibitors are not new to the market, two of them recently gained approval for use in prostate cancer for the first time. The therapies will bring a new option for the treatment of certain subpopulations of patients.

On May 19, the FDA expanded the label of AstraZeneca and Merck & Co., Inc.’s Lynparza (olaparib) to include the treatment of people with deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer who have progressed following treatment with Xtandi (enzalutamide) or Zytiga/Yonsa (abiraterone acetate). Lynparza also has approvals in breast, ovarian and pancreatic cancers.

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/Specialty_article_Anthem_Launches_Voluntary.jpg
September 9

Anthem Launches Voluntary Oncology Dose Reduction Program

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/Specialty_Pharmacy_article_Home_Infusion_Policies.jpg
September 9

Legislation Seeks to Change Medicare Home Infusion Policies

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/Specialty_Pharmacy_article_Specialty_Trend.jpg
September 9

Specialty Trend Increase Slows; Biosimilars Are Having Impact

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today